ASCO has launched a new ACT Network site that makes it easier-than-ever to advocate on behalf of the oncology community. As the online advocacy hub for ASCO advocates, the new ACT Network offers enhanced features that allow advocates to quickly and easily engage their lawmakers on key policy issues.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (BRAFTOVI™ and MEKTOVI®, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
In the latest ASCO in Action Podcast, Dr. Edward Kim, Chair of the Department of Solid Tumor Oncology at the Levine Cancer Institute, joined ASCO CEO Dr. Clifford A. Hudis to discuss eligibility criteria for cancer clinical trials.
The American Medical Association (AMA) Opioid Task Force issued a report documenting physician-driven initiatives to advance the fight against the opioid epidemic in the United States, progress to date, and recommendations to continue to help reverse the epidemic. ASCO has been an active member of the AMA Opioid Task Force since 2017.
ASCO Practice Consulting Services & Support is expanding its offerings to include new clinical consulting services designed to help oncology practices standardize patient care, use their workforce efficiently, and transition patient care to a value-based care delivery model.
The Centers for Medicare & Medicaid Services (CMS) has provided an update on their review of a 2017 Wisconsin Physician Service Insurance Corporation (WPS)—a Medicare Administrative Contractor (MAC)—local coverage decision limiting off-label prescribing.
The Department of Health and Human Services (HHS) has announced further delay for implementation of the updated Common Rule until January 2, 2019.
The Journal of Oncology Practice (JOP) launched a new care delivery blog, JOP DAiS (Discussion & Analysis in Short), to serve as a forum for commentary and analysis on issues affecting the mechanisms of oncology care delivery. This new platform will be a way to collaborate, debate, and discuss many of the topics JOP addresses in its publication including health services research, business and socioeconomics, ethics, and health policy.
A new review article in the Journal of Oncology Practice reexamines the roles of a principal investigator in the current environment of rapid drug discovery and development. The review outlines the increasing responsibilities of a principal investigator, the important role they play in compliance, and how those in the field can prepare to become a successful principal investigator.
On June 15, the Journal of Oncology Practice published an ASCO article examining the state of oncology practice in the United States as part of its new State of Cancer Care in America™ article series. The State of Oncology Practice in America, 2018 reports on important trends in oncology practice ownership, practice concerns, and the oncology workforce, along with details on the size, geographical distribution, and number of practices currently open in the United States.
The findings from the National Youth Tobacco Survey (NYTS) show decreases in the use of cigarettes, cigars, smokeless tobacco, pipes, and bidis, and saw an increase in e-cigarette use from 2011 to 2017.
On June 13, 2018, the Food and Drug Administration approved bevacizumab (Avastin®, Genentech, Inc.) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection. The FDA also accelerated approval to pembrolizumab (Keytruda®, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy.
During the American Medical Association (AMA) House of Delegates (HOD) annual meeting, delegates approved several ASCO-led resolutions and incorporated them into the AMA’s policy agenda.
Right-to-try is the latest topic addressed in the ASCO in Action podcast series. ASCO CEO Dr. Clifford Hudis recently interviewed ASCO Senior Vice President and Chief Medical Officer Dr. Richard Schilsky to examine RTT legislation—now enacted as federal law—and discuss the Food and Drug Administration’s (FDA) expanded access program.
On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda®, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.